Johnson & Johnson

JNJ · NYSE · USD

$262.51−0.84%−$2.23

Close · October 1, 2026

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

Income statement · Annual
Item	2025	2024	2023	2022	2021
Total revenue	94,193	88,821	85,159	79,990	78,740
Cost of revenue	30,065	27,036	26,244	24,596	23,402
Gross profit	64,128	61,785	58,915	55,394	55,338
Selling, general and administrative	23,130	21,952	20,166	19,078	19,506
Research and development	14,665	17,232	15,085	14,135	14,277
Operating income	26,333	22,601	23,664	22,181	21,555
EBIT	26,333	22,601	23,664	22,181	21,555
EBITDA	33,836	29,940	30,767	28,510	28,206
Interest expense	971	755	772	276	183
Pre-tax income	32,581	16,687	15,062	19,359	19,178
Income tax	5,777	2,621	1,736	2,989	1,377
Net income	26,804	14,066	35,153	17,941	20,878
Net income to common shareholders	26,804	14,066	35,153	17,941	20,878
Basic EPS	11.13	5.84	13.88	6.83	7.93
Diluted EPS	11.03	5.79	13.72	6.73	7.81
Average shares (basic)	2,407	2,407	2,534	2,625	2,632
Average shares (diluted)	2,429	2,429	2,560	2,664	2,674
Dividend per share	5.14	4.91	4.70	4.45	4.19